Aardvark Therapeutics Inc
Research Aardvark Therapeutics Inc (AARD) on Bullrun: market cap USD 158.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAARD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 158.66M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 69.87M
- Free cash flow-USD 61.75M
Valuation Snapshot
latest market cap is USD 158.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 57.59M | -USD 54.27M | n/a | -2.93 | USD 47.05M | USD 441.00K | USD 106.63M |
| FY2024 | USD 0 | -USD 20.59M | -USD 18.20M | n/a | -5.15 | USD 61.64M | USD 779.00K | -USD 54.64M |
| FY2023 | USD 0 | -USD 7.21M | n/a | n/a | n/a | USD 9.74M | USD 162.00K | -USD 34.80M |
| FY2022 | USD 0 | -USD 13.56M | n/a | n/a | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 158.66M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 286.44M | n/a | n/a | n/a |
About Aardvark Therapeutics Inc
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aardvark Therapeutics Inc's market cap?
Aardvark Therapeutics Inc's market capitalization is USD 158.66M.
What does Aardvark Therapeutics Inc do?
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.